Marina Vetrova1, Sara Lodi2, Lindsey Rateau2, Gregory Patts2, Elena Blokhina3, Vladimir Palatkin3, Tatiana Yaroslavtseva3, Olga Toussova3, Natalia Bushara3, Sally Bendiks4, Natalia Gnatienko4, Evgeny Krupitsky5, Dmitry Lioznov6, Jeffrey H Samet7, Karsten Lunze8. 1. First Pavlov State Medical University of Saint Petersburg, 6-8 Lev Tolstoy Street, St. Petersburg, 197022, Russia. Electronic address: mvetrova111@gmail.com. 2. Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA. 3. First Pavlov State Medical University of Saint Petersburg, 6-8 Lev Tolstoy Street, St. Petersburg, 197022, Russia. 4. Boston Medical Center, 801 Massachusetts Ave Crosstown, Boston, MA, USA. 5. First Pavlov State Medical University of Saint Petersburg, 6-8 Lev Tolstoy Street, St. Petersburg, 197022, Russia; Bekhterev National Medical Research Center of Psychiatry and Neurology, 3 Bekhterev Street, Saint Petersburg, 192019, Russia. 6. First Pavlov State Medical University of Saint Petersburg, 6-8 Lev Tolstoy Street, St. Petersburg, 197022, Russia; Smorodintsev Research Institute of Influenza, Prof. Popov Street, 15/17, Saint Petersburg, 197376, Russia. 7. Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA; Boston Medical Center, 801 Massachusetts Ave Crosstown, Boston, MA, USA; Boston University School of Medicine, 72 E Concord Street, Boston, MA, 02118,USA. 8. Boston University School of Public Health, 715 Albany Street, Boston, MA, 02118, USA; Boston University School of Medicine, 72 E Concord Street, Boston, MA, 02118,USA.
Abstract
BACKGROUND: HIV-positive people who inject drugs (PWID) are stigmatized and face more challenges in accessing ART. The natural course of stigma and its role on ART initiation in this population is unclear. We examined 1] whether HIV stigma changes over time and 2] whether HIV and substance use stigma are associated with ART initiation in a prospective cohort of HIV-positive PWID in St. Petersburg, Russia. METHODS: We used data from 165 HIV-positive PWID who were ART-naïve at enrollment andgeneralized estimating equations to assess changes in HIV stigma between baseline, 12- and 24-month study visits. Logistic regression estimated associations of HIV stigma and substance use stigma with ART initiation. All models were adjusted for gender, age, CD4 count, duration of HIV diagnosis, recent (past 30-day) drug use and depressive symptoms. RESULTS: Participants characteristics were the following: median age of 34 (Q1; Q3: 30; 37) years; 30% female; 28% with CD4 count <350; 44% reported recent drug use. During the study period, 31% initiated ART and the median time between HIV diagnosis and ART initiation was 8.5 years (Q1; Q3: 4.68; 13.61). HIV stigma scores decreased yearly by 0.57 (95% CI -1.36, 0.22). More than half (27/47 [57.4%]) of participants who were eligible for ART initiation per local ART guidelines did not initiate therapy. Total HIV stigma and substance use stigma scores were not associated with ART initiation (AOR 0.99, 95%CI 0.94-1.04; AOR 1.01, 95%CI 0.96-1.05, respectively). CONCLUSION: In this Russian cohort of HIV-positive, ART-naïve PWID, stigma did not change over time and was not associated with ART initiation. Addressing stigma alone is unlikely to increase ART initiation rates in this population. Reducing further existing structural barriers, e.g., by promoting equal access to ART and the value of substance-use treatment for ART treatment success should complement stigma-reduction approaches.
BACKGROUND: HIV-positive people who inject drugs (PWID) are stigmatized and face more challenges in accessing ART. The natural course of stigma and its role on ART initiation in this population is unclear. We examined 1] whether HIV stigma changes over time and 2] whether HIV and substance use stigma are associated with ART initiation in a prospective cohort of HIV-positive PWID in St. Petersburg, Russia. METHODS: We used data from 165 HIV-positive PWID who were ART-naïve at enrollment andgeneralized estimating equations to assess changes in HIV stigma between baseline, 12- and 24-month study visits. Logistic regression estimated associations of HIV stigma and substance use stigma with ART initiation. All models were adjusted for gender, age, CD4 count, duration of HIV diagnosis, recent (past 30-day) drug use and depressive symptoms. RESULTS: Participants characteristics were the following: median age of 34 (Q1; Q3: 30; 37) years; 30% female; 28% with CD4 count <350; 44% reported recent drug use. During the study period, 31% initiated ART and the median time between HIV diagnosis and ART initiation was 8.5 years (Q1; Q3: 4.68; 13.61). HIV stigma scores decreased yearly by 0.57 (95% CI -1.36, 0.22). More than half (27/47 [57.4%]) of participants who were eligible for ART initiation per local ART guidelines did not initiate therapy. Total HIV stigma and substance use stigma scores were not associated with ART initiation (AOR 0.99, 95%CI 0.94-1.04; AOR 1.01, 95%CI 0.96-1.05, respectively). CONCLUSION: In this Russian cohort of HIV-positive, ART-naïve PWID, stigma did not change over time and was not associated with ART initiation. Addressing stigma alone is unlikely to increase ART initiation rates in this population. Reducing further existing structural barriers, e.g., by promoting equal access to ART and the value of substance-use treatment for ART treatment success should complement stigma-reduction approaches.
Authors: A L Wirtz; C E Zelaya; C Latkin; A Peryshkina; N Galai; V Mogilniy; P Dzhigun; I Kostetskaya; S H Mehta; C Beyrer Journal: Sex Transm Infect Date: 2015-08-21 Impact factor: 3.519
Authors: Yuri A Amirkhanian; Jeffrey A Kelly; Anna V Kuznetsova; Wayne J DiFranceisco; Vladimir B Musatov; Dmitry G Pirogov Journal: AIDS Behav Date: 2011-05
Authors: Thomas P Giordano; Fehmida Visnegarwala; A Clinton White; Catherine L Troisi; Ralph F Frankowski; Christine M Hartman; Richard M Grimes Journal: AIDS Care Date: 2005-08
Authors: Jason B Luoma; Richard H Nobles; Chad E Drake; Steven C Hayes; Alyssa O'Hair; Lindsay Fletcher; Barbara S Kohlenberg Journal: J Psychopathol Behav Assess Date: 2013-06-01
Authors: Samresh Kumar; Himanshu A Gupte; Petros Isaakidis; J K Mishra; Joseph Francis Munjattu Journal: PLoS One Date: 2018-08-30 Impact factor: 3.240
Authors: Valerie A Earnshaw; Laura M Bogart; Jean-Philippe Laurenceau; Brian T Chan; Brendan G Maughan-Brown; Janan J Dietrich; Ingrid Courtney; Gugulethu Tshabalala; Catherine Orrell; Glenda E Gray; David R Bangsberg; Ingrid T Katz Journal: J Int AIDS Soc Date: 2018-10 Impact factor: 5.396
Authors: Kristen S Regenauer; Mary B Kleinman; Jennifer M Belus; Bronwyn Myers; John A Joska; Jessica F Magidson Journal: Drug Alcohol Depend Date: 2022-02-17 Impact factor: 4.492
Authors: Eshan U Patel; Sunil S Solomon; Allison M McFall; Neia Prata Menezes; Cecília Tomori; Aylur K Srikrishnan; Muniratnam S Kumar; David D Celentano; Gregory M Lucas; Shruti H Mehta Journal: AIDS Date: 2022-06-22 Impact factor: 4.632